Table 3. Association between SNP within microRNA binding sites and the prognosis of breast cancer (Stage I).
| SNP | Overall survival | Disease-free survival | |||||||||
| N | HR (95% CI) | P | HR (95% CI) | P# | N | HR (95% CI) | P | HR (95% CI) | P* | ||
| rs1053739 | |||||||||||
| AA | 359 | 1 (ref) | 1 (ref) | 354 | 1 (ref) | 1 (ref) | |||||
| AG | 659 | 1.64 (0.88-3.07) | 0.121 | 2.65 (0.98-7.10) | 0.053 | 656 | 1.27 (0.83-1.95) | 0.270 | 1.24 (0.69-2.21) | 0.471 | |
| GG | 278 | 2.66 (1.37-5.16) | 0.004 | 4.38 (1.52-12.65) | 0.006 | 277 | 1.75 (1.09-2.81) | 0.020 | 1.63 (0.85-3.12) | 0.144 | |
| rs2693 | |||||||||||
| GG | 656 | 1 (ref) | 1 (ref) | 651 | 1 (ref) | 1 (ref) | |||||
| AG | 532 | 1.08 (0.67-1.74) | 0.754 | 0.99 (0.50-1.95) | 0.975 | 529 | 0.90 (0.64-1.28) | 0.568 | 1.05 (0.65-1.71) | 0.837 | |
| AA | 108 | 2.35 (1.22-4.51) | 0.011 | 3.19 (1.01-10.04) | 0.047 | 107 | 1.53 (0.89-2.63) | 0.124 | 1.93 (0.83-4.46) | 0.126 | |
| rs698761 | |||||||||||
| GG | 588 | 1 (ref) | 1 (ref) | 583 | 1 (ref) | 1 (ref) | |||||
| AG | 540 | 0.99 (0.60-1.62) | 0.958 | 1.63 (0.78-3.39) | 0.192 | 536 | 0.93 (0.64-1.34) | 0.683 | 0.99 (0.61-1.61) | 0.977 | |
| AA | 168 | 1.92 (1.07-3.44) | 0.028 | 3.48 (1.45-8.33) | 0.005 | 168 | 1.64 (1.05-2.58) | 0.030 | 0.90 (0.43-1.88) | 0.777 | |
| rs8602 | |||||||||||
| CC | 656 | 1 (ref) | 1 (ref) | 652 | 1 (ref) | 1 (ref) | |||||
| AC | 518 | 1.38 (0.85-2.23) | 0.189 | 1.45 (0.73-2.88) | 0.293 | 514 | 1.05 (0.74-1.49) | 0.781 | 1.04 (0.63-1.70) | 0.886 | |
| AA | 123 | 2.27 (1.19-4.32) | 0.013 | 2.63 (1.04-6.65) | 0.041 | 122 | 1.34 (0.79-2.28) | 0.278 | 1.27 (0.58-2.78) | 0.549 | |
| rs10878441 | |||||||||||
| AA | 476 | 1 (ref) | 1 (ref) | 471 | 1 (ref) | 1 (ref) | |||||
| AC | 610 | 1.00 (0.58-1.70) | 0.986 | 1.09 (0.52-2.29) | 0.811 | 606 | 1.07 (0.72-1.57) | 0.745 | 1.26 (0.74-2.16) | 0.396 | |
| CC | 211 | 2.63 (1.51-4.58) | 0.001 | 2.46 (1.07-5.68) | 0.035 | 211 | 2.11 (1.37-3.25) | 0.001 | 1.83 (0.95-3.55) | 0.071 | |
| rs10318 | |||||||||||
| AA | 351 | 1 (ref) | 1 (ref) | 350 | 1 (ref) | 1 (ref) | |||||
| AG | 660 | 0.75 (0.47-1.21) | 0.242 | 0.47 (0.24-0.94) | 0.033 | 654 | 0.77 (0.53-1.11) | 0.153 | 0.55 (0.32-0.94) | 0.029 | |
| GG | 283 | 0.37 (0.18-0.78) | 0.009 | 0.32 (0.13-0.80) | 0.015 | 281 | 0.64 (0.39-1.03) | 0.064 | 0.63 (0.34-1.20) | 0.161 | |
| rs10075853 | |||||||||||
| AA | 802 | 1 (ref) | 1 (ref) | 798 | 1 (ref) | 1 (ref) | |||||
| AG | 412 | 1.32 (0.82-2.14) | 0.256 | 1.22 (0.60-2.46) | 0.583 | 407 | 1.15 (0.81-1.64) | 0.436 | 1.34 (0.82-2.17) | 0.243 | |
| GG | 83 | 2.52 (1.30-4.91) | 0.006 | 3.58 (1.26-10.14) | 0.017 | 83 | 1.34 (0.73-2.46) | 0.343 | 1.08 (0.45-2.61) | 0.857 | |
| rs8410 | |||||||||||
| GG | 599 | 1 (ref) | 1 (ref) | 593 | 1 (ref) | 1 (ref) | |||||
| AG | 532 | 0.95 (0.58-1.56) | 0.840 | 1.63 (0.78-3.40) | 0.191 | 529 | 0.88 (0.61-1.26) | 0.480 | 0.98 (0.60-1.59) | 0.934 | |
| AA | 163 | 1.98 (1.11-3.54) | 0.021 | 3.63 (1.52-8.71) | 0.004 | 163 | 1.60 (1.01-2.51) | 0.043 | 0.84 (0.39-1.80) | 0.647 | |
SNP, single-nucleotide polymorphism; HR, hazard ratio; CI, confidence interval.
#Adjusted for age at diagnosis, education, occupation, age at menarche, number of live births, breastfeeding duration, abortion, menopause, TNM stage, tumor size, histopathologic classification, grade, lymph node, ER, PR, and HER2.
*Adjusted for age at diagnosis, number of live births, breastfeeding duration, abortion, menopause, benign breast disease, TNM stage, tumor size, histopathologic classification, grade, lymph node, ER, PR, and HER2.